The collaboration contributes to climate commitments Neste made in 2020, including a commitment to reduce and compensate emissions from its employees’ business travel through the use of the company’s own sustainable aviation fuel.
…
…
Neste and NuStar Energy are also teaming up on supplying SAF to California airports. Supply trucks are now able to load Neste MY Sustainable Aviation Fuel at the NuStar-operated Selby Terminal near San Francisco, California. The first gallons have been safely picked up and delivered to the nearby Monterey Regional Airport. Due to the strategic location of the Selby Terminal, Neste and its partners Avfuel and Signature Flight Support are now able to supply sustainable aviation fuel to a growing number of airports across the western United States. In 2020, Neste established a continuous supply of SAF to San Francisco International Airport from NuStar’s Selby Terminal using an existing pipeline – a first for the industry.
There were 22 weekdays in April. There were 15 announcements about sustainable aviation fuel progress, advancements, implementations, and production in just those 21 days. What does that mean? Why is SAF suddenly taking off like never before, even as the aviation industry was turned upside down due to the COVID-19 pandemic? Why are companies pivoting from other fuels to focus on SAF?
In today’s Digest, let’s kick the tires and light the fires as SAF is cleared for take-off. The latest SAF news and what it means.
Neste’s News
Let’s start with the most recent big news that Neste will convert up to 500,000 tons of its existing renewables production capacity at Rotterdam refinery for SAF. Currently the refinery produces mainly Neste MY Renewable Diesel. The modifications to the refinery, an investment of approximately EUR 190 million, will enable Neste to optionally produce up to 500,000 tons of SAF per annum as part of the existing capacity.
BSC Counselor - Patricio O’Donnell, M.D., Ph.D.
Patricio O’Donnell, M.D., Ph.D. is Executive Medical Director in the Translational Research and Early Clinical group at Takeda Pharmaceuticals. He received his M.D. and Ph.D. (in Physiology) degrees from the University of Buenos Aires, Argentina. After a residency in Internal Medicine, he did a postdoctoral fellowship at the University of Pittsburgh with Tony Grace. He spent the next 16 years in academia, first at Albany Medical College and later at the University of Maryland School of Medicine. His academic career focused on translational studies to understand the neuronal circuitry implicated in neuropsychiatric disorders. In 2013, Patricio was recruited by Pfizer to lead discovery efforts for psychiatric indications. In that role, he led a variety of internal efforts and external collaborations aimed at identifying genetically-informed novel targets, as well as finding biomarkers for patient stratification. At Takeda, he leads s
Anti-Obesity Drugs Market Research Report - Global Forecast to 2025 - Cumulative Impact of COVID-19 Anti-Obesity Drugs Market Research Report - Global Forecast to 2025 - Cumulative Impact of COVID-19 Market Statistics: The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD.
April 29, 2021 05:04 ET | Source: ReportLinker ReportLinker Lyon, FRANCE
New York, April 29, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Anti-Obesity Drugs Market Research Report - Global Forecast to 2025 - Cumulative Impact of COVID-19 - https://www.reportlinker.com/p06067147/?utm source=GNW This helps organization leaders make better decisions when currency exchange data is readily available.
POLITICO
The most promising coronavirus vaccine you’ve never heard of
Novavax’s rise comes as pressure to increase the supply of Covid-19 vaccines is growing amid concerns that unequal access globally will extend the pandemic.
Swabs from patients participating in the Novavax Phase III Covid-19 clinical vaccine trial await testing in Seattle, Wash. | Karen Ducey/Getty Images
Link Copied
Hopes are growing that a dark-horse coronavirus vaccine from a tiny U.S. drugmaker can shore up supplies in the U.S. and globally as safety concerns and production problems shadow shots from Johnson & Johnson and AstraZeneca.
The vaccine’s developer, Novavax, has never brought a product to market. The shot entered late-stage clinical trials months